Murky Response Measures Shouldn’t Block Accelerated Approval Of GSK’s Arzerra, ODAC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting at the ASCO annual meeting, the panel votes 10-3 that an ORR of 42 percent is likely to predict clinical benefit in chronic lymphocytic leukemia patients refractory to two drugs.